Lakefront Biotherapeutics Repurchases €2.73M in Shares Under Ongoing Program
LKFT sits 16% above its 52-week low of $26.42.
Summary
Lakefront Biotherapeutics reports repurchasing €2.73 million of its shares, continuing its previously announced €50 million buyback program.
Key Events · Financing and Capital Events · LKFT
-
Share Repurchase Update
Lakefront Biotherapeutics repurchased 104,022 shares for a total of €2.73 million between June 29 and July 3, at an average price of €26.24 per share.
-
Ongoing Buyback Program
These repurchases are part of the €50 million stock repurchase program initiated on June 9, 2026, signaling continued capital return to shareholders.
Analysis · LKFT · Life Sciences
Lakefront Biotherapeutics has repurchased €2.73 million worth of its own shares between June 29 and July 3, as part of the €50 million stock repurchase program announced on June 9. This ongoing execution of the buyback program demonstrates the company's commitment to returning capital to shareholders and can support earnings per share.
At the time of this filing, LKFT was trading at $30.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $26.42 to $37.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.